Disclaimer: This Blog owner & creator is not a research analyst and expresing opinion only as an Investor in Indian equities with his vast experience.He is not responsible for any loss arising out of any information, post or opinion appearing on this blog. Investors are advised to consult financial consultant before acting on any such information.Any query mail me firstname.lastname@example.org
Today we are discussing very interesting one stock for medium to long term investments.
Jeevan Scientific Technology Ltd
Jeevan Scientific Technology Limited, established in the year 1999,
is a global management consulting, technology services and outsourcing
company located in Hyderabad, India.
Jeevan has been designed with state of the art facility
to provide a broad range of clinical research services for
healthcare/pharmaceutical industries across the globe.
Jeevan is a perfect blend of technology, innovation and
expertise, which enables it to provide reliable, cost-effective and
technology driven services and solutions to the clients across the
Jeevan offers wide range of clinical services in association with
various major Indian CROs and hospitals.
We execute trials with ample efforts and ensure that the trial is
conducted as per the protocol and applicable guidelines/ regulations.
Jeevan is committed to ensure patient rights, safety and data integrity.
Jeevan’s clinical operations technical team applies their therapeutic, regulatory and operational expertise to
consistently solve the challenges that arise during all clinical trial projects.
Clinical Data Management
Clinical Data Management (CDM) is a critical phase in
clinical research and the integrity of clinical data is of paramount
importance to a successful project. Jeevan ensures the
integrity by strict adherence to established standard operating and
review procedures at every stage of project, including
complete large and complex clinical programs. Our data is delivered with
quality assurance at every step and data management systems
are in compliance with FDA 21 CFR Part 11 and industry guidelines for
Promoter holding good 41% stake in company, jstl posted 4 cr top line and 0.15 cr bottom line in latest quarter. This company having good business model bring more growth in coming years, so investor can buy this stock @ current price and hold medium to long term in their portfolio.Stock trading only in BSE @ 46 level.
Before buying any stock take advice from certified person.